Tiffany Thorn
Founder en BIVICTRIX THERAPEUTICS PLC .
Fortuna: 232 011 $ al 31/03/2024
Perfil
Tiffany Thorn is the founder and currently serves as the Chief Executive Officer & Executive Director of BiVictriX Therapeutics Plc, which is founded in 2016.
She previously served as the Chief Executive Officer & Director of Motif Bio Plc.
Ms. Thorn is a graduate of The University of Manchester and holds an undergraduate degree from the University of Lancaster.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/12/2022 | 1 632 500 ( 1.98% ) | 232 011 $ | 31/03/2024 |
Cargos activos de Tiffany Thorn
| Empresas | Cargo | Inicio |
|---|---|---|
| BIVICTRIX THERAPEUTICS PLC | Founder | 01/01/2016 |
Antiguos cargos conocidos de Tiffany Thorn.
| Empresas | Cargo | Fin |
|---|---|---|
| MOTIF BIO PLC | Chief Executive Officer | - |
Formación de Tiffany Thorn.
| The University of Manchester | Graduate Degree |
| University of Lancaster | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
| BiVictriX Therapeutics Plc | |
Motif Bio Plc
 Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Tiffany Thorn
